John Libbey Eurotext

Gériatrie et Psychologie Neuropsychiatrie du Vieillissement


Vitamin D supplementation and COVID-19: expert consensus and guidelines Ahead of print

1 Département de gériatrie et Centre mémoire ressources recherche, Centre de recherche sur l’autonomie et la longévité, Centre hospitalier universitaire, Angers, France; UPRES EA 4638, Université d’Angers, Angers, France; Gérontopôle Autonomie Longévité des Pays de la Loire, Nantes, France
2 Service des explorations fonctionnelles, Hôpital Necker-Enfants malades, AP-HP Paris, France
* Correspondence

After 12 months of viral circulation, the SARS-CoV-2 has infected millions of people around the world, leaving hundreds of thousands dead. Given the lack of effective therapy and vaccination against COVID-19, focusing on the immediate repurposing of existing drugs gives some hope of curbing the pandemic. Vitamin D is a possible candidate drug which is discussed in a high number of publications. Randomised clinical trials have shown that vitamin D supplementation significantly reduces the risk of respiratory infections. There is also a great deal of evidence that hypovitaminosis D is an independent (and easily modifiable) risk factor for severe forms of COVID-19 and death. Vitamin D supplementation is a simple, safe and inexpensive measure, which is effective in correcting hypovitaminosis D, present in 40–50% of the French population and in more than 80% of adults with COVID-19. In this position paper, we propose simple regimens (adapted to the pharmaceutical forms currently available in France) for vitamin D supplementation in adults with or without COVID-19.